Clinical Trial Update: EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes for Epstein-Barr virus–associated lymphomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoproliferative Disorder
• Non-hodgkin Lymphoma

Drugs mentioned

• EBV-specific T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder | Phase 1 | Status: RECRUITING